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Abstract
Oxidative stress acts as a double‐edged sword by being both a promoter and a
suppressor of cancer. Moderate oxidative stress is beneficial for cancer cell
proliferative and invasiveness features, while overexposure of the cells to
oxidative insults could induce cancer cell apoptosis and reduce hypoxia along
with modulating the immune system for regression of tumor. Cancer cells and
cancer stem cells have highly efficient redox systems that make them resistant
to oxidative insults. The redox disruptive approach is an area of current research
and key for oxidative targeted cancer therapies. This disruption is applicable by
using either oxidative or anti‐oxidative overloading strategies, specifically on
cancer cells without influencing normal cells or tissues around tumor. The
activity of tumor suppressor cells within tumor microenvironment is needed to
be maintained in patients receiving such approaches.
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1 | INTRODUCTION
Oxidative stress and related signaling pose a great
challenge for anticancer therapies. This is due to its
dichotomous role of being both pro‐ and anti‐tumor.
Reactive oxygen species (ROS) are byproducts of cellular
metabolism, which play cardinal roles for promotion of
tumorigenesis and also for directing responses from
cancer cells to anti‐tumor therapy.1 Modulation of ROS is
a common outcome of most radio‐ and chemotherapeutic
drugs used for the treatment of cancer.2
ROS can be both inhibitors and activators of cancer‐
promoting mediators.3,4 Bulk cancer cells and cancer stem
cells (CSCs) are highly sensitive to any alterations in
their intracellular redox state.5 This sensitivity is
dependent, to a great extent, on the ROS concentration. A
high ROS concentration could be therapeutic via induction
of apoptotic‐related mediators. By contrast, activation of
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anti‐oxidative enzymes after reduction of intracellular ROS
levels could be a promoter of cancer cell proliferation.1 ROS
concentration in cancer cells is modified through mito-
phagy‐related processes in which a huge increase in ROS
concentration formed in the early phase mitophagy is
counteracted and modified in the late phase through
noticeable attenuation of ROS production.6 CSCs maintain
ROS levels to low amounts, which is mainly due to the
expression of ROS scavenging molecules and their efficient
DNA repair systems, thereby promoting resistance to
oxidative targeted therapies.2 Actually, the controlled
release of ROS to the TME provides an immune escape
mechanism for cancer cells in attaining their proliferative
and invasive features.7
Interestingly, activation of both oxidative and antioxida-
tive machineries is therapeutic; both of these induce cancer
cell apoptosis. The antioxidative system would do such a
work through activation of endoplasmic reticulum stress.8
This is a virtue for cancer targeted therapies by overloading
cancer cells with either system in favor of cancer retardation.
In this review, we intended to focus on how oxidative
stress could take two opposite schemes in cancer, and
how to push these two diverse destinations for cancer‐
targeted therapies. The general subjects in this regard
have not been discussed (like oxidative stress as a general
subject, sources of ROS within the cell, and anti‐oxidative
enzymes), as they have been clearly illustrated by other
researchers and by us.9 With an ever‐growing rise in the
knowledge about oxidative stress and the related plethora
of fates, we hope to design more specific therapeutic
approaches for cancer. The PubMed database was
searched for relevant articles in this context. The criteria
for article selection were based on the quality of journals
and the novelty of subjects presented by the relevant
articles. About 150 papers were scanned for this review
by searching the key words “oxidative stress” and
“cancer;” among them, about 30 papers met the criteria
for further discussion.
2 | EVIDENCE FOR
ANTI ‐TUMOR ACTIVITY
OF OXIDATIVE STRESS
Macrophages are considered as one of the leading cells in the
immune system and represent up to 50% of infiltrated cells to
the stroma of tumor.10 These cells have key interactions with
other cells of tumor stroma for the hampering or promotion
of cancer.11 A cardinal characteristic for macrophages is their
plasticity and their potential to tailor responses depending on
signals received from stroma of tumors.12 Generally,
macrophages are classified into two extremes: M1 and M2
cells.10 M1 cells are classically activated cells that have a
proinflammatory phenotype with antitumor activity, while
M2 cells are alternatively activated cells that have immuno-
suppressive features for progression of cancer.12 Increase in
ROS levels in antitumor M1 phenotype of macrophages not
only increases their number through activation of the NF‐κB‐
mediated pathway,10 but also induces tumoricidal activity in
cells.13
Regulatory T cells (Tregs) are another immune cells that
are frequently found in the tumor TME.14 An increase in the
number for Tregs in the TME indicates immunosuppression
in the milieu, which is essential for cancer cells to escape
from the immune system posing as a main obstacle for
cancer therapy.15 Tregs are attributed to monocyte differ-
entiation toward M2 phenotype,15 which, in turn, are
responsible for the recruitment of Tregs to the TME for
exerting tumor progressive roles.16 The protumor Tregs are
highly sensitive to oxidative conditions, in which an increase
in the production of ROS would cause a decrease in the
number of these tumor promoting cells.17 Moreover, over
release of ROS to the cytosol of cancer cells could induce
membrane permeability transition pores for releasing
cytochrome c and further activation of apoptotic‐related
caspase cascades.1
It seems that moderate production of ROS by cancer cells
acts as an inducer of hypoxia, and it has been understood
from a large number of papers that hypoxia and related
processes play key roles in progression of cancer.13,16,18-21 By
contrast, ROS overload to the TME could act as an inhibitor
for the release of hypoxic mediators from cancer cells,19,22
Interestingly, hypoxia, in an indirect reciprocal feedback
(through induction of autophagy responses), reduces ROS
production by cancer cells19 (Figure 1).
3 | EVIDENCE FOR PRO ‐TUMOR
ACTIVITY OF OXIDATIVE STRESS
Cancer associated fibroblasts (CAFs) are key components of
tumor stroma,23 which in the initial tumorigenic stages,
presumably play antitumor roles through TME remodeling
functions; while with an increase in the rate of tumor
growth, the cells play a diverse role by acting as tumor
promoters.24 CAFs express and secrete a myriad of factors
related to reprogramming cancer cells along with cells within
cancer stroma, like macrophages and endothelial cells to
facilitate cancer cell invasive traits.23,24 Oxidative stress plays
a cardinal role for differentiation of fibroblasts toward CAFs.
The NADPH oxidase (NOX) system is a main source of ROS
within the cells. Cancer cells have highly compatible NOX
systems.25,26 A type of NOX that has been identified to play
an important role in cancer progression is NOX4. NOX4 has
been attested to play roles for transdifferentiation of
fibroblasts into their activated CAF phenotypes.27
72 | FARHOOD ET AL.
Oxidative stress facilitates crosstalks between CAFs and
cancer cells. Oxidative stress induces release of high‐energy
nutrients from tumor stroma essential for fueling cancer cells
to facilitate their growth and survival.28 ROS accumulation in
cancer cells promotes immune escape in the cells, resistance
to apoptosis, and cancer recurrence.29-31 In addition, cancer
cells' release of ROS to the TME is detected by CAFs for
promotion of angiogenesis‐related mediators, like VEGF.2
Oxidative stress also induces senescence in both CAFs and
cancer cells. Senescent CAFs release numerous cytokines,
proteases, and growth factors to promote invasion and
migration of cancer cells.28 Senescence may also take another
way by suppressing tumor progression32 (Figure 1).
Oxidative stress could also exhaust natural killer (NK)
cell functioning, providing an immune escape within the
TME for cancer cell invasion. To do this, cancer cells
release H2O2 to the TME, which is able to switch off the
function of NK cells.7
4 | DISRUPTION OF THE REDOX
BALANCE WITHIN THE TUMOR
AS A PROMISING THERAPEUTIC
APPROACH
There is evidence frommost of the reports studied so far that
disruption of the redox balance in the tumor would be a
promising therapeutic approach. It is interesting to note that
cancer cells are highly compatible to maintaining a redox
balance for attaining progression‐related features. These cells
have high rates of oxidative stress as well as increased activity
of antioxidative related enzymes.33 When the rate of ROS
production in the cells reaches an undesired state, the
antioxidative machinery is activated to keep the cells in a
proactive position. This is a striking characteristic for cancer
cells, allowing them to acquire resistance to oxidative
inducers. Therefore, cancer cells can easily adopt to new
environments because they have highly compatible oxidative
and antioxidative machineries, allowing them to induce a
new redox balance for the promotion of tumor growth. To
maintain a redox balance, cancer cells have a high‐quality
NOX system for the promotion of tumor growth and
invasiveness.25,26
The current research has focused on the disruption of
the redox system in cancer cells. Photodynamic therapy34
and nanoparticle delivery techniques35 are examples of
the techniques used in the immunotherapy of cancer, and
their focus is to mediate over‐increase of ROS deposition
within the TME. One of the important ways to reach to
this aim is by manipulating NOX activity in cancer.
Overrelease of ROS to the TME is an inhibitor for release
of hypoxic mediators.19,22 These mediators play cardinal
roles for amplification of cancer‐promoting events. A
point in this context is to apply therapeutic procedures
specifically on cancer cells and their related milieu
(ie TME). Overload of ROS on normal cells around
cancer can induce mitochondrial dysfunctions in the
cells, which, in turn, through promoting a vicious cycle
could increase the rate of mutations in mitochondrial
DNA, favoring cancer progression in normal cells.36
Another point to consider is that due to oxidation‐
induced NK exhaustion resulting in immunosuppression,
patients receiving oxidative overloading therapy are recom-
mended to also receive factors for activation of NK cells.
There is evidence that when NK cells are activated, the cells
become resistant to oxidative overloading therapy. These
cells are activated by application of interleukins 2 and 15
inducers. These inducers would maintain the redox balance
within NK cells as well as cytotoxic T lymphocytes (CTLs)
through upregulation of peroxiredoxin‐1 in the cells.7
Therefore, to have an appropriate therapeutic response, the
redox system is needed to be disrupted within cancer cells,
but this system must be maintained in a balance for tumor
suppressor cells like NK and CTL cells.
FIGURE 1 Evidence for pro‐ and anti‐tumoral roles for oxidative stress. Oxidative stress could target cancer cells and cancer associated
fibrolasts (CAFs) to be tumorigenic. For suppression of tumor, macrophages, regulatory T cells (Tregs) and cancer cells are targeted by
oxidative stress
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Cancer‐targeted therapy can also be applied through over
release of antioxidative related molecules to the tumor
milieu. This is also applicable for the disruption of the redox
system in cancer cells. This antioxidative delivery could be
applied through exogenous administration of antoxidative
hormones like melatonin, which has long been known for its
tremendous anticancer potentials.1,9 Inhibitors of oxidative
inducers like cyclooxygenase 2 (COX‐2), nitric oxide
synthase, and NOX system are other tools for shifting the
redox system toward an antioxidative overloading (Figure 2).
An important point to consider is that oxidative system
is one of (not specific) the targets for these anticancer
approaches. So, it may target signals that are more potent
than oxidative targeting for retarding cancer. For example,
melatonin, as the most potent anti‐oxidative hormone for
treatment of cancer, could take several roles independent
of its antioxidative function. Another point is that
induction of one pathway by oxidative or antioxidative
systems could diversely activate an undesirable pathway in
favor of cancer progression. For example, ROS intrusion to
the TME could induce apoptosis in Tregs, and there is
evidence their its being more pro‐active of these apoptotic
cells in promotion of immune escape than their live
counterparts.37 This is also applicable for cancer cell
apoptosis mediated by oxidative stress. Apoptotic cancer
cells release apoptotic vesicles for stimulation of invasion
in CAFs.38 Increase of the activity for caspase‐1 in tumor
associated macrophages (TAMs) is also tumorigenic
through increase of lipid deposition within the cells along
with release of lactate to the TME.39 However, there is no
compelling evidence for a possible relationship between
oxidative/anti‐oxidative overloading with apoptosis induc-
tion in the TAMs, which is needed to be investigated in
future studies. The point we could focus on here is that
cancer cells, along with the cells within the stroma
of tumor, are equipped with sophisticated mechanisms
to make the stroma conditioned for modulating any
alterations in oxidative/anti‐oxidative status in their favor.
Therefore, the knowledge presented in this review could
not be deemed as a concept of a cancer targeted therapy
for disrupting the redox system, although it is important
and would be a dominant player. Instead, this is needed to
be applied in adjuvan e with other therapeutic strategies
like chemo‐ or radio‐therapy to disrupt the accessory
mechanisms activated by cells within the TME, and
thereby having a desirable anti‐cancer therapy. We hope
that with broadening knowledge regarding dominant
players in cancer would make the road smoother for
cancer‐targeted therapies.
5 | CONCLUSION
Oxidative/anti‐oxidative overloading therapy has focused
on the three criteria: (1) to disrupt the redox balance in
cancer through cancer cell overloading with either
oxidative or anti?oxidative machinery; (2) to maintain
the activity of tumor suppressor cells within the TME;
and (3) to prevent the influence of such an approach on
normal cells or tissues around the tumor.
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